نتایج جستجو برای: moxifloxacin hydrochloride

تعداد نتایج: 46374  

Journal: :The Journal of infectious diseases 2004
Tawanda Gumbo Arnold Louie Mark R Deziel Linda M Parsons Max Salfinger George L Drusano

BACKGROUND Moxifloxacin is a quinolone antimicrobial that has potent activity against Mycobacterium tuberculosis. To optimize moxifloxacin dose and dose regimen, pharmacodynamic antibiotic-exposure targets associated with maximal microbial kill and complete suppression of drug resistance in M. tuberculosis must be identified. METHODS We used a novel in vitro pharmacodynamic infection model of...

Journal: :Antimicrobial agents and chemotherapy 2008
Kelly Dooley Charles Flexner Judith Hackman Charles A Peloquin Eric Nuermberger Richard E Chaisson Susan E Dorman

Moxifloxacin- and rifapentine-based regimens are under investigation for the treatment of tuberculosis. However, rifapentine may induce enzymes that metabolize moxifloxacin, resulting in decreased moxifloxacin concentrations. In this phase I, two-period, sequential-design study, 13 subjects received 400 mg moxifloxacin daily for 4 days followed by daily moxifloxacin coadministered with 900 mg r...

2012
C. M. Modi S. K. Mody F. D. Modi H. B. Patel

This study describes disposition of long-acting moxifloxacin and conventional formulations of moxifloxacin in sheep after intravenous administration in five male sheep. Long acting moxifloxacin solution (10% moxifloxacin in solution with L-arginine, N-butyl alcohol, and benzyl alcohol) and conventional moxifloxacin (10%) were injected in jugular vein. Blood samples were collected from contralat...

Journal: :iranian journal of pharmaceutical research 0
effat souri - farzaneh sadat ahmadi dept of pharmaceutical chemistry, faculty of pharmacy, azad university sedighe fadaye vatan research and development, kish medipharm company majid mohammad hosseini research and development, kish medipharm company

buprenorphine is a partial mu agonist and kappa antagonist which is used for the treatment of pain and opioid addiction. a mixture of buprenorphine hydrochloride and naloxone hydrochloride has been approved for the treatment of opioid dependence.in this study a third order derivative spectrophotometric method based on zero-crossing technique has been used for the simultaneous determination of b...

Journal: :American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2007
Richard G Fiscella Charles C Lewis Michael K Jensen

PURPOSE The utilization and refill rates of topical ophthalmic fourth-generation fluoroquinolones among physicians, as well as the associated costs, were studied. METHODS A large data set of retrospective pharmacy prescription claims was obtained from multiple plans, including commercial managed care organizations, Medicaid, and Medicare. The data included the number and cost of all new and r...

2012
Syed Naeem Razzaq

A simple, RP-HPLC method was established for determining moxifloxacin and ketorolac in pharmaceutical formulations. Moxifloxacin, ketorolac and their degradation products were separated using C8 column with methanol and phosphate buffer pH 3.0 (55:45 v/v) as the mobile phase. Detection was performed at 243 nm using a diode array detector. The method was validated using ICH guidelines and was li...

Journal: :Antimicrobial agents and chemotherapy 2009
Cécile Denève Sylvie Bouttier Bruno Dupuy Frédéric Barbut Anne Collignon Claire Janoir

Recent outbreaks of Clostridium difficile infection have been related to the emergence of the NAP1/027 epidemic strain. This strain demonstrates increased virulence and resistance to the C-8-methoxyfluoroquinolones gatifloxacin and moxifloxacin. These antibiotics have been implicated as major C. difficile infection-inducing agents. We investigated by real-time reverse transcription-PCR the impa...

2012
Wilhelm Haverkamp Frank Kruesmann Anna Fritsch David van Veenhuyzen Pierre Arvis

Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in a large patient population from Phase II-IV randomized active-controlled clinical trials. Moxifloxacin 400 mg once-daily monotherapy was administered orally (PO) or sequentially (intravenous/oral, IV/PO). Across 64 trials, 21,298 patients received PO therapy (10,613 moxifloxacin, 10,685 comparators) while...

2014
Mohammed M Hefnawy Atef M Homoda Mohammed A Abounassif Amer M Alanazi Abdulrahaman Al-Majed Gamal A Mostafa

BACKGROUND The construction and electrochemical response characteristics of Poly (vinyl chloride) membrane sensors for moxifloxacin HCl (MOX) are described. The sensing membranes incorporate ion association complexes of moxifloxacin cation and sodium tetraphenyl borate (NaTPB) (sensor 1), phosphomolybdic acid (PMA) (sensor 2) or phosphotungstic acid (PTA) (sensor 3) as electroactive materials. ...

2012
David P. Holland Gillian D. Sanders Carol D. Hamilton Jason E. Stout

BACKGROUND The optimal treatment for latent multiple-drug resistant tuberculosis infection remains unclear. In anticipation of future clinical trials, we modeled the expected performance of six potential regimens for treatment of latent multiple-drug resistant tuberculosis. METHODS A computerized Markov model to analyze the total cost of treatment for six different regimens: Pyrazinamide/etha...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید